Canopy Hauptforum WKN: A3E2FV ISIN: CA1380357048 Forum: Aktien User: Marindigo

Ja richtig, aber für eine gewisse nachhaltigkeit bräuchte es mehr wie ein intraday Anstieg Kurz über den doller.

Erklärung für den Cashburn, EBITDA-/Profitabilitätsausblick und Aussagen zu Canopy USA/US-Regulierung sind im call interessant. Bezüglich dem Cashburn wären Aussagen wie; „Der höhere Cash-Abfluss in Q1 wurde wesentlich durch temporäre Working-Capital-Effekte, Timing von Zahlungen oder einmalige Kosten verursacht und sollte sich in den kommenden Quartalen normalisieren.“ Das wäre nochmal eher positiver zu bewerten.

Noch ist der Call nicht zu Ende....

Tageshoch war schon bei 1,02$!!! Der Tag ist noch lang ✌️😎🚀🚀🚀

Auch wichtig das die 0,95 jetzt erstmal wieder eine Unterstützung und kein Wiederstand mehr sind. Der heutige Tag war damit die beschriebene Bestätigung die ich am Dienstag meinte, auch wenn es ein Tag später erst der Fall ist. Wichtig werden jetzt die kommenden Handelstage werden, hier wäre natürlich schön zu sehen das sich der Kurs nachhaltiger den doller Krallt. 1,02-1,05 $ wäre ganz interessant vorerst.

Geduld kennt er nicht

Ich denke, bottom ist drin ✌️🎯

Nachgelegt 💪💪

💸💸💸💸

Die Amis haben gerade mal 26 Minuten geöffnet und du heulst hier schon wieder rum. Wir wäre es erstmal den Earnings Call abzuwarten?

Leider nicht mehr

Nach nicht mal 5 Minuten so viel Volumen wie gestern den ganzen Tag

Oh der doller ist schon geknackt. Hoffentlich kein kurzes Vergnügen

Executive summary Achieved consolidated net revenue of $81.2M in Q1 FY2027, up 13% year-over-year, with growth across all business segments. Net loss decreased by 68% compared to Q1 FY2026, reflecting improved profitability measures. Adjusted EBITDA loss narrowed by 59% year-over-year to $3.2M, driven by revenue growth and cost savings. Integration of MTL Cannabis contributed to increased supply, expanded revenue, and meaningful synergies. Financial highlights Cannabis net revenue rose 14% year-over-year to $65.1M, with Canadian medical cannabis up 22%, Canadian adult-use up 10%, and international markets up 10%. Storz & Bickel net revenue increased 6% to $16.1M. Consolidated gross margin improved to 27% from 25% year-over-year; adjusted gross margin rose to 31%. Storz & Bickel gross margin surged to 48% from 29% due to cost rationalization and tariff recovery. Free cash outflow increased to $25.7M from $11.6M, mainly due to working capital changes. Outlook and guidance Anticipates further financial improvements in the second half of FY2027 as MTL Cannabis integration completes. Strategies in place to drive growth in all end markets, focusing on cultivation and high-quality flower supply. Segment performance Canadian medical cannabis: $25.8M net revenue (+22%), driven by more insured customers and MTL Cannabis acquisition. Canadian adult-use cannabis: $29.7M net revenue (+10%), with increased flower sales offset by lower bulk sales. International cannabis: $9.6M net revenue (+10%), led by European growth, especially Poland. Storz & Bickel: $16.1M net revenue (+6%), with gross margin improvement to 48%. Key financial ratios and metrics Adjusted gross margin: 31% (up from 25% year-over-year). Cannabis segment adjusted gross margin: 26% (up from 24%). Storz & Bickel segment adjusted gross margin: 48% (up from 29%). Adjusted EBITDA loss: $3.2M, improved by $4.7M year-over-year. Basic and diluted loss per share: $(0.03), improved from $(0.24) year-over-year. Risk factors and uncertainties Exposed to regulatory changes, evolving U.S. cannabis laws, and risks from integration of acquisitions. Faces macroeconomic risks, including inflation, tariffs, and supply chain disruptions. Subject to risks from impairment of intangible assets, liquidity, and compliance with debt covenants. Significant events and developments Apollo Cannabis Clinics named Best Medical Cannabis Clinic in Toronto Star Readers' Choice Awards. Relaunched Tweed brand in Germany, leveraging MTL Cannabis genetics. Improved adult-use market ranking to #6 in Canada, with top 2 positions in premium flower and infused pre-rolls. Unveiled refreshed corporate identity to reflect evolution into a modern cannabis company. Capital allocation and financing Cash and cash equivalents at quarter-end: $336.6M. Issued common shares and warrants, raising $38.3M in the quarter. Repayment of long-term debt and payment of debt issue costs during the quarter. Market and industry conditions Benefited from increased demand in both medical and adult-use cannabis markets in Canada and Europe. Maintained strong brand presence and expanded product offerings in competitive Canadian market.